- Home
- DGICB vs XNCR Comparison
DGICB vs XNCR Comparison
Compare DGICB & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICB
- XNCR
- Stock Information
- Founded
- DGICB 1986
- XNCR 1997
- Country
- DGICB United States
- XNCR United States
- Employees
- DGICB N/A
- XNCR N/A
- Industry
- DGICB Property-Casualty Insurers
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- DGICB Finance
- XNCR Health Care
- Exchange
- DGICB Nasdaq
- XNCR Nasdaq
- Market Cap
- DGICB 605.9M
- XNCR 579.3M
- IPO Year
- DGICB N/A
- XNCR 2013
- Fundamental
- Price
- DGICB $19.40
- XNCR $8.54
- Analyst Decision
- DGICB
- XNCR Buy
- Analyst Count
- DGICB 0
- XNCR 7
- Target Price
- DGICB N/A
- XNCR $27.50
- AVG Volume (30 Days)
- DGICB 419.0
- XNCR 791.6K
- Earning Date
- DGICB 07-24-2025
- XNCR 08-04-2025
- Dividend Yield
- DGICB 3.75%
- XNCR N/A
- EPS Growth
- DGICB 1206.68
- XNCR N/A
- EPS
- DGICB 2.03
- XNCR N/A
- Revenue
- DGICB $993,637,805.00
- XNCR $127,228,000.00
- Revenue This Year
- DGICB $3.27
- XNCR N/A
- Revenue Next Year
- DGICB $4.01
- XNCR $28.84
- P/E Ratio
- DGICB $9.57
- XNCR N/A
- Revenue Growth
- DGICB 5.29
- XNCR N/A
- 52 Week Low
- DGICB $10.75
- XNCR $7.16
- 52 Week High
- DGICB $18.83
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- DGICB 67.35
- XNCR 44.94
- Support Level
- DGICB $17.00
- XNCR $8.05
- Resistance Level
- DGICB $17.98
- XNCR $10.20
- Average True Range (ATR)
- DGICB 0.42
- XNCR 0.57
- MACD
- DGICB 0.02
- XNCR -0.01
- Stochastic Oscillator
- DGICB 77.78
- XNCR 31.40
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.